Meniscus tears, patellar tendonitis, ACL strains, chronic osteoarthritis — knee injuries are one of the most common reasons people try BPC-157. Here's the evidence and the standard protocol.
Animal studies show accelerated collagen organization and tensile strength in Achilles and patellar tendon repair. Mechanism: VEGFR2 upregulation and growth-factor modulation at injury sites.
Downregulates inflammatory cytokines (TNF-α, IL-1β) locally. Particularly relevant for chronic knee OA where low-grade inflammation perpetuates cartilage breakdown.
New blood vessel formation brings nutrients + growth factors to poorly-perfused tissues like tendons and menisci. The primary mechanism for soft-tissue healing acceleration.
Subcutaneous injection near the injury (proximal/distal to the knee) provides higher local concentration. Systemic SC injection at any site also works. Both are used in protocols.
User reports cluster around 2-4 weeks for subjective improvement and 6-12 weeks for functional recovery. Animal studies show measurable histological changes within similar windows. If nothing shifts by week 6, consider adding TB-500 or reassessing.
No — systemic SC at any site works mechanistically. Local injection provides higher concentration at the target tissue, which some clinicians prefer for recalcitrant injuries. Abdominal fat is the standard site if local injection isn't convenient.
Meniscus has poor vascularity, especially in the inner third. BPC-157's angiogenesis mechanism is particularly interesting here. User reports are mixed — meniscus takes longer than tendon/ligament, and complete tears often still need surgical repair.
For acute injuries, BPC-157 alone is often sufficient. For chronic pain, recurrent injury, or complex issues, the combo is worth considering. TB-500 adds cell migration to BPC's angiogenesis — complementary mechanisms.
Swiss Chems publishes third-party HPLC COAs for every batch. HighPeptides' primary vendor reference for peptides.
Browse Swiss Chems →Affiliate link — supports HighPeptides at no extra cost
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
BPC-157 is not FDA-approved for human use. It's sold for research purposes only. The protocols described are based on animal research and user reports, not confirmed by human RCTs.
Acute knee injuries warrant orthopedic evaluation. BPC-157 is not a substitute for proper medical diagnosis and treatment. Not medical advice.